🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

449 results for “Sun” Clear

  1. GLS4

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chronic HBV Infection

    phase 2 small molecule completed

    1 trial

  2. GLS4

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chronic Hepatitis B

    phase 2 small molecule completed

    3 trials

  3. Gazyvaro 1,000 mg concentrate for solution for infusion., Columvi 10 mg concentrate for solution for infusion, Columvi 10 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., BGB-11417, Zanubrutinib, Mosunetuzumab, Columvi 10 mg concentrate for solution for infusion, Columvi 10 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., BGB-11417, BGB-16673, Gazyvaro 1,000 mg concentrate for solution for infusion., BGB-11

    BEONE MEDICINES AUS PTY LTD

    Relapsed or Refractory B-Cell Malignancies

    phase 2 small molecule active

    1 trial

  4. Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, JNJ-42756493, Gemcitabine 2 g Powder for Solution for Infusion, JNJ-42756493, JNJ-42756493, Mitomycin medac 1 mg/ml Pulver zur Herstellung einer Injektions- bzw. Infusionslösung oder einer Lösung zur intravesikalen Anwendung

    Janssen-Cilag International N.V.

    Cohort 1 and 2: High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions Cohort 3 Intermediate Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions

    phase 2 small molecule active

    1 trial

  5. Gemcitabine+simvastatin

    Samsung Bioepis NL B.V.

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  6. HEC110114 tablet

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chronic Hepatitis C

    phase 2 small molecule completed

    2 trials

  7. HEC121120 tablets

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Hepatitis B, Chronic

    phase 2 small molecule terminated

    1 trial

  8. HEC169096

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  9. HEC585

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    5 trials

  10. HEC585 dose A

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)

    phase 2 small molecule active

    1 trial

  11. HEC96719

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Non-Alcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  12. HRS-7058

    Shandong Suncadia Medicine Co.,

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  13. HYDROXYCARBAMIDE , BEVACIZUMAB , SUNITINIB , OCTREOTIDE , EVEROLIMUS , Lutathera 370 MBq/mL solution for infusion

    Ningbo Cancer Hospital

    Recurrent Meningioma without local treatment options (Surgery or Radiotherapy)

    phase 2 small molecule active

    1 trial

  14. Herceptin 150 mg powder for concentrate for solution for infusion, Enhertu 100 mg powder for concentrate for solution for infusion, Fluorouracil Injection, 50 mg/ml, solution for injection, Ziihera 300 mg powder for concentrate for solution for infusion., Kadcyla 160 mg powder for concentrate for solution for infusion., Calciumfolinat Kabi 10 mg/ml Injektions-/Infusionslösung, Oxaliplatin Hikma 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Xeloda 500 mg film-coated tablets, Xeloda 150 mg film-co

    Boehringer Ingelheim

    gastroesophageal junction adenocarcinoma, metastatic gastric adenocarcinoma, metastatic breast cancer, metastatic colorectal cancer, esophageal adenocarcinoma

    phase 2 small molecule active

    1 trial

  15. Injection of humanized nerve growth factor (NGF) antibody

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Cancer Pain

    phase 2 small molecule active

    1 trial

  16. Irinotecan Hikma 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Oxaliplatin Hikma 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, FLUOROURACIL , IRINOTECAN , Fluorouracil Hikma 50 mg/ml Injektionslösung, Ribofolin® 10 mg/ml Injektionslösung, JNJ-61186372, OXALIPLATIN , CALCIUM FOLINATE , JNJ-61186372, BENDAFOLIN 10 mg/ml Injektionslösung, 5-FU medac 50 mg/ml, Injektionslösung

    Janssen-Cilag International N.V.

    Advanced or Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  17. Irinotecan Hikma 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, PALBOCICLIB, Palbociclib, TEMOZOLOMIDE, TEMOZOLOMIDE, PALBOCICLIB, PALBOCICLIB, TEMOZOLOMIDE, Temozolomide SUN 5 mg hard capsules, Endoxan®, TOPOTECANE ACCORD 1 mg/ml, solution à diluer pour perfusion

    Pfizer Australia Pty Ltd

    recurrent/refractory Ewing sarcoma, recurrent or refractory neuroblastoma

    phase 2 small molecule active

    1 trial

  18. Isatuximab, Dexa-ratiopharm® 8 mg Injektionslösung, Fortecortin® 2 mg Tabletten, Revlimid 15 mg hard capsules, Zelvina 2.5 mg hard capsules, Revlimid 10 mg hard capsules, Revlimid 2.5 mg hard capsules, Zelvina 5 mg hard capsules, Zelvina 25 mg hard capsules, Imnovid 2 mg hard capsules, Imnovid 3 mg hard capsules, Zelvina 10 mg hard capsules, Revlimid 25 mg hard capsules, Imnovid 1 mg hard capsules, Dexamethason 8 mg GALEN® Tabletten, Nirogacestat, Isatuximab, Nirogacestat, Dexa 8 mg inject JENAPHARM Injekti

    GlaxoSmithKline

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  19. Isatuximab, Kyprolis 60 mg powder for solution for infusion, METHYLPREDNISOLONE , MONTELUKAST , DexaGalen® 8 mg injekt Injektionslösung, DIPHENHYDRAMINE , Dexamethason 4 mg JENAPHARM®, Dr. Reddy's Carfilzomib, PARACETAMOL

    Sanofi-aventis Healthcare Pty Ltd

    Cancer - Relapsed/refractory multiple myeloma

    phase 2 small molecule active

    1 trial

  20. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Acasunlimab

    Genmab A/S

    Malignant Solid Tumors - Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  21. KN046 （PD-L1/CTLA4 BsAb）

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced HCC

    phase 2 small molecule terminated

    1 trial

  22. Letybo® 50 Einheiten Pulver zur Herstellung einer Injektionslösung, Letybo 50 Einheiten Pulver zur Herstellung einer Injektionslösung

    Lacuna Pharma Pty Ltd

    Moderate and severe horizontal forehead lines.

    phase 2 small molecule active

    1 trial

  23. Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion, TAXOTERE 20 mg/1 ml concentrate for solution for infusion, medoxa 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, IMFINZI 50 mg/mL concentrate for solution for infusion., 5-FU medac 50 mg/ml, Injektionslösung

    The George Institute

    T1-T2N0 esophageal adenocarcinoma including gastroesophageal junction (GEJ) with indication for radical surgery

    phase 2 small molecule active

    1 trial

  24. Lytgobi 4 mg film-coated tablets, 5-FU medac 50 mg/ml, Injektionslösung, Oxaliplatin Kabi 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Tevimbra 100 mg concentrate for solution for infusion, Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion

    The George Institute

    Colorectal cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources